Cargando…
Janssen/Johnson & Johnson COVID-19 vaccine-related GBS in USA
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8532479/ http://dx.doi.org/10.1007/s40278-021-03977-1 |
Ejemplares similares
-
Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19
Vaccine — United States, March–April 2021
por: Shay, David K., et al.
Publicado: (2021) -
Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021
por: Oliver, Sara E., et al.
Publicado: (2022) -
A case report of vaccine-induced immune thrombocytopenia and thrombosis syndrome after Ad26.COV2.S vaccine (Janssen/Johnson & Johnson)()
por: Castan, Maxime, et al.
Publicado: (2022) -
TTS with Janssen's COVID-19 vaccine
Publicado: (2021) -
Anxiety disorders with Janssen's COVID-19 vaccine
Publicado: (2021)